Daiichi Sankyo announced a partnership with U.S. Summit to develop combination therapies for Datroway. JCR Pharma entered into a licensing agreement with Italfarmaco for the sale and development of Izcargo in the U.S. and Europe. Other reports included Taiho Pharmaceutical beginning its U.S. filing, Santen Pharmaceutical transferring AVS, and Maruishi Pharmaceutical and Mune Pharmaceutical forming a capital and business alliance.
On 2 October, Daiichi Sankyo announced that it would partner with Summit Therapeutics of the U.S. to develop combination therapies for Datroway, an antibody-drug conjugate. The primary targets are lung and breast cancers, among others, and the companies will begin a Phase 3 clinical trial intended as first-line treatment for triple-negative breast cancer. Ivonescimab was discovered by China's Akeso, which has partnered with Summit on its development and commercialization in the U.S., Europe and Japan.
On 2 October, JCR Pharma announced that it had entered into a licensing agreement with Italfarmaco for the development and commercialization of Izcargo, a treatment for Hunter syndrome, in the U.S., Europe and Latin America. Italfarmaco will handle sales and distribution, while JCR will be responsible for manufacturing.
Taiho Pharmaceutical, a subsidiary of Otsuka Holdings, began filing in the U.S. for a combination therapy of zipalertinib and chemotherapy. The indication is previously untreated locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. The company plans to complete the review by the end of the year under the FDA's Real-Time Oncology Review program.
Santen Pharmaceutical transferred all shares of AVS, its ophthalmic medical device subsidiary, to U.S.-based SpyGlass Pharma. AVS will remain involved in the Japanese market, and Santen will continue to receive supplies of intraocular lens products.
Maruishi Pharmaceutical and Mune Pharmaceutical announced a capital and business alliance. Maruishi Pharmaceutical will subscribe to Mune Pharmaceutical's third-party allotment of new shares, and the two companies will strengthen their long-standing relationship in the manufacture and sale of Mune glycerin enemas.